<?xml version="1.0" encoding="UTF-8"?>
<p>Guidance issued by the major UK non-commercial funding bodies stated that funding for trials in progress would not be affected by the temporary halt of the trial due to COVID-19, in the short term, and/or that the continuation of funding and no-cost extensions will be assessed on a case-by-case basis [
 <xref rid="REF5" ref-type="bibr">5</xref>-
 <xref rid="REF7" ref-type="bibr">7</xref>]. We recognised that responses and interpretation of these directives varied on both a trial and institutional level. Therefore, we sought to describe and understand the decisions and action in response to COVID-19 for clinical trials of investigational medicinal products (CTIMPs) that were relevant to older adults and those with neurological conditions. These groups were chosen as a subset of those classed by the UK government as 'clinically vulnerable people' who were advised to take particular care to minimise contact with others outside their household [
 <xref rid="REF8" ref-type="bibr">8</xref>].
</p>
